Oramed Pharmaceuticals (NASDAQ:ORMP) COO Sells 30,000 Shares of Company Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) COO Joshua Hexter sold 30,000 shares of Oramed Pharmaceuticals stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $135,300.00. Following the sale, the chief operating officer directly owned 1,328,130 shares of the company’s stock, valued at approximately $5,989,866.30. This trade represents a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oramed Pharmaceuticals Trading Up 0.2%

Shares of ORMP stock traded up $0.01 on Friday, reaching $4.49. 178,322 shares of the stock were exchanged, compared to its average volume of 227,288. The business’s 50 day moving average price is $4.64 and its 200 day moving average price is $4.19. The company has a market capitalization of $186.78 million, a price-to-earnings ratio of 1.09 and a beta of 1.29. Oramed Pharmaceuticals Inc. has a twelve month low of $2.09 and a twelve month high of $5.47.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its earnings results on Monday, August 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.52). Equities research analysts forecast that Oramed Pharmaceuticals Inc. will post 1.47 earnings per share for the current year.

Institutional Trading of Oramed Pharmaceuticals

A number of large investors have recently bought and sold shares of ORMP. SB Capital Management Inc purchased a new position in Oramed Pharmaceuticals during the 4th quarter worth $5,415,000. Dimensional Fund Advisors LP increased its stake in Oramed Pharmaceuticals by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after purchasing an additional 7,738 shares during the period. Ritholtz Wealth Management purchased a new stake in shares of Oramed Pharmaceuticals in the first quarter valued at about $529,000. Bank of America Corp DE raised its holdings in shares of Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 3,909 shares during the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new stake in shares of Oramed Pharmaceuticals in the first quarter valued at about $331,000. Institutional investors and hedge funds own 12.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wall Street Zen upgraded Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings restated a “hold (c+)” rating on shares of Oramed Pharmaceuticals in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, Oramed Pharmaceuticals presently has an average rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) is a biopharmaceutical company focused on developing orally administered therapies that are traditionally delivered by injection. The company’s technology is designed to protect therapeutic proteins and peptides as they pass through the digestive system and facilitate their absorption in the body.

Oramed’s lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) analog candidate.